title: Fractionated administration of gemtuzumab ozogamicin for refractory acute myeloid leukemia.
abstract: It is difficult to decide an appropriate treatment strategy for elderly leukemia patients with other complications. We encountered 2 cases of refractory acute myeloid leukemia and safely treated the patients with fractionated administration of gemtuzumab ozogamicin (GO). Standard induction therapies were not effective for these patients. Moreover, they suffered from complications due to which their treatment options were restricted. Fractionated administration of GO (GO 3 mg/m(2) on days 1, 3 and 5) was accomplished safely and alleviated the patients' conditions. After treatment, these patients were followed by outpatient basis. We consider that this is an impressive treatment because fractionated administration of GO is potentially less toxic. Further, it will be helpful to maintain or improve the QOL of patients who are unable to receive intensive chemotherapy. These cases were significant because fractionated GO treatment is potentially less toxic and it will be helpful to maintain or improve the QOL of patients who can not receive intensive chemotherapy.
authors.affiliation: Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: YAHAGI
authors.forename: Noriko
authors.initials: N
authors.lastname: USUI
authors.forename: Yuko
authors.initials: Y
authors.lastname: YAMAGUCHI
authors.forename: Nobuaki
authors.initials: N
authors.lastname: DOBASHI
authors.forename: Shingo
authors.initials: S
authors.lastname: YANO
authors.forename: Yutaka
authors.initials: Y
authors.lastname: TAKEI
authors.forename: Katsuki
authors.initials: K
authors.lastname: SUGIYAMA
authors.forename: Shinobu
authors.initials: S
authors.lastname: TAKAHARA
authors.forename: Takeshi
authors.initials: T
authors.lastname: SAITO
authors.forename: Jiro
authors.initials: J
authors.lastname: MINAMI
authors.forename: Tatsunosuke
authors.initials: T
authors.lastname: KOBAYASHI
authors.forename: Yutaro
authors.initials: Y
authors.lastname: KAMIYAMA
authors.forename: Tetsuyuki
authors.initials: T
authors.lastname: MORIKAWA
authors.forename: Keisuke
authors.initials: K
authors.lastname: AIBA
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab